Natriumchlorid Kabipac (Sodium Chloride)

Sodium Chloride, the active ingredient in Natriumchlorid Kabipac, is an electrolyte presented as an injection solution for intravenous use. It restores extracellular sodium and chloride concentrations and expands intravascular volume, supporting fluid replacement in patients with hypovolemia or hyponatremia.

GNH USA supplies Natriumchlorid Kabipac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, including acute care settings.

Natriumchlorid Kabipac, an intravenous sodium chloride solution, is used in fluid and electrolyte replacement therapy. - Hypovolemia: restores intravascular volume and improves circulatory stability. - Hyponatremia: increases serum sodium concentration to correct electrolyte imbalance. - Fluid replacement during surgery or trauma: provides isotonic fluid to maintain hemodynamic parameters. - Electrolyte replenishment in burn patients: supplies chloride and sodium to support metabolic needs.

Intravenous sodium chloride may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Injection site pain or irritation. - Mild hypernatremia. - Transient hypertension. - Fluid overload (edema).

Serious or Rare Side Effects: - Severe hypernatremia leading to neurologic symptoms. - Pulmonary edema. - Allergic reaction or anaphylaxis. - Metabolic alkalosis.

Before using Natriumchlorid Kabipac, clinicians should consider several safety measures. - Assess volume status: evaluate patient’s fluid balance prior to infusion. - Monitor electrolytes: check serum sodium and chloride levels regularly. - Avoid rapid infusion in patients at risk of heart failure: follow recommended infusion rates. - Use caution in renal impairment: adjust volume as needed. - Pregnancy and lactation: limited data, weigh benefits against potential risks. - Store at ambient temperature: keep in original container, protect from light and moisture.

Natriumchlorid Kabipac can interact with other medications, requiring careful management.

Major Interactions (Avoid): - Concurrent use of hypertonic saline solutions: risk of severe hypernatremia. - Combination with diuretics that cause sodium loss: may counteract therapeutic effect. - Co‑administration with drugs that increase fluid retention (e.g., corticosteroids) without monitoring.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may affect renal handling of sodium. - Lithium therapy: sodium shifts can alter lithium levels. - Nephrotoxic antibiotics (e.g., aminoglycosides): monitor renal function.